Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menstrual cycle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Quality of life and micronised progesterone (200 mg) in adolescent menstrual cycle disorders
    Active substance: ESTRADIOL
    Study summary document link (including results):
    View full study record
    Document reference: 26628
    Study title: "Quality of life and micronised progesterone (200 mg) in adolescent menstrual cycle disorders"
    Active substance: PROGESTERONE
    Study summary document link (including results): EUdraCT_reduced datafields for Interim publication_Besins.xls
    View full study record
    Document reference: 34993
    Study title: Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. Facina G, Rodrigues De LG, Simoes MJ, Novo NF, Gebrim LH. International Journal of Gynecology and Obstetrics 1997;56(1):19-24 1997;(1):19-24.Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. Facina G, Rodrigues De LG, Simoes MJ, Novo NF, Gebrim LH. International Journal of Gynecology and Obstetrics 1997;56(1):19-24 1997;(1):19-24.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43295
    Study title: Facina G, Rodrigues De LG, Simoes MJ, Novo NF, Gebrim LH. Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. International Journal of Gynecology and Obstetrics 1997; 56(1):19-24.Facina G, Rodrigues De LG, Simoes MJ, Novo NF, Gebrim LH. Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. International Journal of Gynecology and Obstetrics 1997; 56(1):19-24.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43153
    Study title: Uehara J, Nazario ACP, Rodrigues De LG, Simoes MJ, Juliano Y, Gebrim LH. Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle. International Journal of Gynecology and Obstetrics 1998; 62(1):77-82.Uehara J, Nazario ACP, Rodrigues De LG, Simoes MJ, Juliano Y, Gebrim LH. Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle. International Journal of Gynecology and Obstetrics 1998; 62(1):77-82.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43151
    Study title: Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle. Uehara J, Nazario ACP, Rodrigues De LG, Simoes MJ, Juliano Y, Gebrim LH. International Journal of Gynecology and Obstetrics 1998;62(1):77-82 1998;(1):77-82.Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle. Uehara J, Nazario ACP, Rodrigues De LG, Simoes MJ, Juliano Y, Gebrim LH. International Journal of Gynecology and Obstetrics 1998;62(1):77-82 1998;(1):77-82.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43293
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:47:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA